AXA Framlington Biotech R Class Acc

Performance History30/06/2018
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc
Fund45.311.2-5.98.57.1
+/-Cat6.7-2.3-1.9-1.72.2
+/-B’mrk6.3-2.7-10.70.65.9
 
Key Stats
NAV
13/07/2018
 GBX 197.30
Day Change 2.07%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
31/05/2018
 GBP 491.11
Share Class Size (Mil)
13/07/2018
 GBP 135.56
Max Initial Charge 5.50%
Ongoing Charge
19/02/2018
  1.82%
Investment Objective: AXA Framlington Biotech R Class Acc
The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.
Returns
Trailing Returns13/07/2018
YTD16.81
3 Years Annualised2.97
5 Years Annualised16.02
10 Years Annualised18.94
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMSCI World/Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech R Class Acc31/05/2018
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.640.0098.64
Bond0.000.000.00
Property0.000.000.00
Cash1.110.500.60
Other0.760.000.76
Top 5 Regions%
United States87.86
United Kingdom4.96
Eurozone4.79
Europe - ex Euro1.90
Canada0.49
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Biogen IncHealthcareHealthcare10.12
Alexion Pharmaceuticals IncHealthcareHealthcare6.51
Celgene CorpHealthcareHealthcare6.08
Gilead Sciences IncHealthcareHealthcare5.04
Vertex Pharmaceuticals IncHealthcareHealthcare4.35
AXA Framlington Biotech R Class Acc